3 pg/ml (range, 43.0-5556.3 pg/ ml). Serum
DKK-1 levels did not correlate with those of AFP or des-γ-carboxy prothrombin (DCP). When cut off value of 450 pg/ml was used, sensitivity U0126 datasheet and specificity of DKK-1 for HCC were 26.8% and 88.9%, respectively. HpSC-HCCs showed poor prognosis with high serum DKK-1 levels compared with MH-HCCs who received surgery, and HCC patients showed elevation of DKK-1 (DKK-1 high HCC) showed a significantly high frequency of portal vein invasion (p < 0.001). Among Barcelona Clinic Liver Cancer (BCLC) stage C patients treated with sorafenib or hepatic arterial infusion chemotherapy using interferon-α/5-FU/cisplatin, DKK-1high HCCs showed a significantly poor prognosis compared with DKK-1 low HCCs (median overall survival 10.6 vs. 13.2 months: p=0.03, and 4.1 vs. 26.7 months: p=0.01, respectively). The expression of DKK1 was correlated to the EpCAM expression, in vitro. Furthermore, anti-DKK1 antibody administration suppressed tumor formation ability of EpCAM-positive HCC cells,
in vivo(p=0.044). Conclusions Serum DKK-1 is elevated in HCC with stem cell features. The poor response of DKK-1 high HCCs to sorafenib or cytotoxic reagents warrants the needs for the development of a novel treatment strategy against this deadly HCC subtype. Disclosures: AP24534 nmr Shuichi Kaneko – Grant/Research Support: MDS, Co., Inc, Chugai Pharma., Co., Inc, Toray Co., Inc, Daiichi Sankyo., Co., Inc, Dainippon Sumitomo, Co., Inc, Ajinomoto Co., Inc, MDS, Co., Inc, Chugai Pharma., Co., Inc, Toray Co., Inc, Daiichi Sankyo., Co., Inc, Dainippon Sumitomo, Co., Inc, Ajinomoto Co., Inc, Bayer Japan The following people have nothing to disclose: Hajime Sunagozaka, Taro Yamashita, Naoki Oishi, Takehiro Hayashi, Hajime Takatori, Tetsuro Shimakami, Kazuya Kitamura,
Kuniaki Arai, Takashi Kagaya, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda Background: Hepatocellular carcinoma (HCC) is one of the cancer types with poor prognosis. At present, serum tumor markers of HCC such as alpha-fetoprotein (AFP), prothrombin induced by vitamin K absence II (PIVKA II) or alpha-fetoprotein Lens culinaris agglutinin 3 (AFP-L3%) are not adequate to predict survival or recurrence after curative hepatectomy. We reported Fatty Acid Binding Protein 5 (FABP5) was a significant prognostic and recurrence factor medchemexpress for HCC patients by immunohistochemical analysis and showed positive correlation of tumor size, intrahepatic metastasis, and micro/macro vascular invasion (Ohata T, et al. AASLD Liver Meeting 2013). Purposes: To examine a correlation between the expression of FABP5 and malignant behavior of HCC using human HCC cell lines. Methods: Protein expression of FABP5 in HCC cell lines (HLE, HLF, Li7, HepG2 and Hep3B) was assessed by western blot analysis. Lentiviral short-hairpin RNA (shRNA) vectors were used to suppress FABP5 expression in higher expression cells or lentiviral overexpression vectors to express FABP5 in lower expression cells.